Canada secures vaccine supply beyond 2021
The agreement guarantees access to 65 million doses of Pfizer-BioNTech’s COVID-19 vaccine, with access to up to 120 million more if all options are exercised.
In addition to providing booster vaccine doses, the agreement provides flexibility to procure future COVID-19 vaccine formulations from Pfizer, such as those to protect against variants of concern and vaccines developed for children.
Importantly, these doses are in addition to the 48 million doses of Pfizer-BioNTech’s COVID-19 vaccine arriving before the end of September 2021 as part of Canada’s existing agreement.
Canada’s existing bilateral agreement with Pfizer is for up to 76 million doses of its mRNA vaccine BNT162, 48 million of which will be delivered before the end of September 2021.
As part of the new agreement with Pfizer:
• Canada has secured access to a guaranteed 35 million doses of Pfizer-BioNTech’s COVID-19 vaccines for 2022, with options for up to 30 million more.
• For 2023, Canada has secured access to a guaranteed 30 million doses, with options for 30 million more.
• 2024 is an option year. If this option is exercised, Canada will have access to another 30 million doses, with options for an additional 30 million. ■